Cargando…

CRISPR/Cas9-mediated targeted gene correction in amyotrophic lateral sclerosis patient iPSCs

Amyotrophic lateral sclerosis (ALS) is a complex neurodegenerative disease with cellular and molecular mechanisms yet to be fully described. Mutations in a number of genes including SOD1 and FUS are associated with familial ALS. Here we report the generation of induced pluripotent stem cells (iPSCs)...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Lixia, Yi, Fei, Fu, Lina, Yang, Jiping, Wang, Si, Wang, Zhaoxia, Suzuki, Keiichiro, Sun, Liang, Xu, Xiuling, Yu, Yang, Qiao, Jie, Belmonte, Juan Carlos Izpisua, Yang, Ze, Yuan, Yun, Qu, Jing, Liu, Guang-Hui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Higher Education Press 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5413600/
https://www.ncbi.nlm.nih.gov/pubmed/28401346
http://dx.doi.org/10.1007/s13238-017-0397-3
_version_ 1783233212110077952
author Wang, Lixia
Yi, Fei
Fu, Lina
Yang, Jiping
Wang, Si
Wang, Zhaoxia
Suzuki, Keiichiro
Sun, Liang
Xu, Xiuling
Yu, Yang
Qiao, Jie
Belmonte, Juan Carlos Izpisua
Yang, Ze
Yuan, Yun
Qu, Jing
Liu, Guang-Hui
author_facet Wang, Lixia
Yi, Fei
Fu, Lina
Yang, Jiping
Wang, Si
Wang, Zhaoxia
Suzuki, Keiichiro
Sun, Liang
Xu, Xiuling
Yu, Yang
Qiao, Jie
Belmonte, Juan Carlos Izpisua
Yang, Ze
Yuan, Yun
Qu, Jing
Liu, Guang-Hui
author_sort Wang, Lixia
collection PubMed
description Amyotrophic lateral sclerosis (ALS) is a complex neurodegenerative disease with cellular and molecular mechanisms yet to be fully described. Mutations in a number of genes including SOD1 and FUS are associated with familial ALS. Here we report the generation of induced pluripotent stem cells (iPSCs) from fibroblasts of familial ALS patients bearing SOD1 (+/A272C) and FUS (+/G1566A) mutations, respectively. We further generated gene corrected ALS iPSCs using CRISPR/Cas9 system. Genome-wide RNA sequencing (RNA-seq) analysis of motor neurons derived from SOD1 (+/A272C) and corrected iPSCs revealed 899 aberrant transcripts. Our work may shed light on discovery of early biomarkers and pathways dysregulated in ALS, as well as provide a basis for novel therapeutic strategies to treat ALS. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s13238-017-0397-3) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5413600
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Higher Education Press
record_format MEDLINE/PubMed
spelling pubmed-54136002017-05-18 CRISPR/Cas9-mediated targeted gene correction in amyotrophic lateral sclerosis patient iPSCs Wang, Lixia Yi, Fei Fu, Lina Yang, Jiping Wang, Si Wang, Zhaoxia Suzuki, Keiichiro Sun, Liang Xu, Xiuling Yu, Yang Qiao, Jie Belmonte, Juan Carlos Izpisua Yang, Ze Yuan, Yun Qu, Jing Liu, Guang-Hui Protein Cell Research Article Amyotrophic lateral sclerosis (ALS) is a complex neurodegenerative disease with cellular and molecular mechanisms yet to be fully described. Mutations in a number of genes including SOD1 and FUS are associated with familial ALS. Here we report the generation of induced pluripotent stem cells (iPSCs) from fibroblasts of familial ALS patients bearing SOD1 (+/A272C) and FUS (+/G1566A) mutations, respectively. We further generated gene corrected ALS iPSCs using CRISPR/Cas9 system. Genome-wide RNA sequencing (RNA-seq) analysis of motor neurons derived from SOD1 (+/A272C) and corrected iPSCs revealed 899 aberrant transcripts. Our work may shed light on discovery of early biomarkers and pathways dysregulated in ALS, as well as provide a basis for novel therapeutic strategies to treat ALS. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s13238-017-0397-3) contains supplementary material, which is available to authorized users. Higher Education Press 2017-04-11 2017-05 /pmc/articles/PMC5413600/ /pubmed/28401346 http://dx.doi.org/10.1007/s13238-017-0397-3 Text en © The Author(s) 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Research Article
Wang, Lixia
Yi, Fei
Fu, Lina
Yang, Jiping
Wang, Si
Wang, Zhaoxia
Suzuki, Keiichiro
Sun, Liang
Xu, Xiuling
Yu, Yang
Qiao, Jie
Belmonte, Juan Carlos Izpisua
Yang, Ze
Yuan, Yun
Qu, Jing
Liu, Guang-Hui
CRISPR/Cas9-mediated targeted gene correction in amyotrophic lateral sclerosis patient iPSCs
title CRISPR/Cas9-mediated targeted gene correction in amyotrophic lateral sclerosis patient iPSCs
title_full CRISPR/Cas9-mediated targeted gene correction in amyotrophic lateral sclerosis patient iPSCs
title_fullStr CRISPR/Cas9-mediated targeted gene correction in amyotrophic lateral sclerosis patient iPSCs
title_full_unstemmed CRISPR/Cas9-mediated targeted gene correction in amyotrophic lateral sclerosis patient iPSCs
title_short CRISPR/Cas9-mediated targeted gene correction in amyotrophic lateral sclerosis patient iPSCs
title_sort crispr/cas9-mediated targeted gene correction in amyotrophic lateral sclerosis patient ipscs
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5413600/
https://www.ncbi.nlm.nih.gov/pubmed/28401346
http://dx.doi.org/10.1007/s13238-017-0397-3
work_keys_str_mv AT wanglixia crisprcas9mediatedtargetedgenecorrectioninamyotrophiclateralsclerosispatientipscs
AT yifei crisprcas9mediatedtargetedgenecorrectioninamyotrophiclateralsclerosispatientipscs
AT fulina crisprcas9mediatedtargetedgenecorrectioninamyotrophiclateralsclerosispatientipscs
AT yangjiping crisprcas9mediatedtargetedgenecorrectioninamyotrophiclateralsclerosispatientipscs
AT wangsi crisprcas9mediatedtargetedgenecorrectioninamyotrophiclateralsclerosispatientipscs
AT wangzhaoxia crisprcas9mediatedtargetedgenecorrectioninamyotrophiclateralsclerosispatientipscs
AT suzukikeiichiro crisprcas9mediatedtargetedgenecorrectioninamyotrophiclateralsclerosispatientipscs
AT sunliang crisprcas9mediatedtargetedgenecorrectioninamyotrophiclateralsclerosispatientipscs
AT xuxiuling crisprcas9mediatedtargetedgenecorrectioninamyotrophiclateralsclerosispatientipscs
AT yuyang crisprcas9mediatedtargetedgenecorrectioninamyotrophiclateralsclerosispatientipscs
AT qiaojie crisprcas9mediatedtargetedgenecorrectioninamyotrophiclateralsclerosispatientipscs
AT belmontejuancarlosizpisua crisprcas9mediatedtargetedgenecorrectioninamyotrophiclateralsclerosispatientipscs
AT yangze crisprcas9mediatedtargetedgenecorrectioninamyotrophiclateralsclerosispatientipscs
AT yuanyun crisprcas9mediatedtargetedgenecorrectioninamyotrophiclateralsclerosispatientipscs
AT qujing crisprcas9mediatedtargetedgenecorrectioninamyotrophiclateralsclerosispatientipscs
AT liuguanghui crisprcas9mediatedtargetedgenecorrectioninamyotrophiclateralsclerosispatientipscs